{"filings":[{"id":1177276,"accession_number":"0001213900-26-070378","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2026-06-22T12:02:58+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nutriband enters amended $5M credit line at 7% interest for AVERSA Fentanyl","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$5M credit line facility amended as of June 1, 2026, replacing prior $5M facility expiring July 2026.","Interest at 7% per annum; no conversion rights for lender into common stock.","Proceeds for commercialization of AVERSA Fentanyl, including FDA submission and manufacturing costs with Kindeva Drug Delivery.","Maturity date July 1, 2029; advances allowed only after commencement of NDA-related work with Kindeva."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94608,"accession_number":"0001213900-26-041006","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband selects brand name for abuse-deterrent fentanyl patch; will submit to FDA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selected commercial worldwide brand name candidate for lead product, a fentanyl transdermal system with abuse-deterrent technology.","Will submit proposed brand name and labeling to FDA and international regulators for review and approval; also filing for trademark registration.","Engaged Brand Institute, global leader with 75% share of drug name approvals and 87% of FDA-approved names in 2024.","Product uses AVERSA abuse-deterrent technology; potential peak annual US sales of $80-200 million per market report.","Brand Institute's regulatory subsidiary DSI, led by former FDA/EMA officials, will provide regulatory support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107117,"accession_number":"0001213900-26-016550","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband terminates sale of Pocono Pharmaceuticals to Earth Vision Bio due to buyer default","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved immediate termination of Pocono Pharmaceuticals sale to Earth Vision Bio Inc.","Purchaser failed to close by December 31, 2025 and did not pay applicable late fees.","Nutriband received $30,000 in late fees but no further payments since January 21, 2026.","Company will retain ownership of Pocono Pharmaceuticals after terminated agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107116,"accession_number":"0001213900-26-011304","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Nutriband shareholders approve preferred share increase from 10M to 20M; two new directors appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized preferred shares from 10,000,000 to 20,000,000 with 86.25% of votes cast in favor.","All seven director nominees elected; Gareth Sheridan received 87.96% of shares voted.","Ratification of Sadler, Gibb & Associates as independent auditor for 2025 passed with 87.59% of votes.","Non-binding say-on-pay and say-on-frequency proposals approved (87.78% and 87.16% respectively).","Board appointed Alessandro Puddu (Italian accountant) and Viorica Carlig (aircraft services manager) as new directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123454,"accession_number":"0001213900-25-126650","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband sells 90% stake in Pocono Pharma for $5M to EarthVision Bio; retains 10%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Agreement to sell 90% interest in subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio.","Nutriband shareholders will retain 10% stake in EarthVision Bio post-acquisition; closing expected Dec 31, 2025.","Proceeds will fund continued development of AVERSA Fentanyl, an abuse-deterrent opioid patch.","AVERSA Fentanyl has potential annual US sales estimate of $80M to $200M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123453,"accession_number":"0001213900-25-102930","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband receives FDA feedback on AVERSA FENTANYL CMC plans; regulatory pathway confirmed as 505(b)(2)","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA meeting held September 18, 2025; final minutes received; feedback on CMC, registration batch, and stability plans.","FDA confirmed 505(b)(2) NDA path and provided guidance on reference drug bridging strategy.","Company plans to file IND to support a Human Abuse Potential clinical study for the abuse-deterrent fentanyl patch.","Partner Kindeva to develop AVERSA FENTANYL combining Nutriband's AVERSA technology with Kindeva's FDA-approved fentanyl patch.","Peak annual US sales potential estimated at $80M to $200M per market analysis report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140127,"accession_number":"0001213900-25-083882","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband discloses option/warrant exercises from Feb-Jul 2025 totaling 845K shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock options exercised on 20,055 shares for $44,206 total exercise price.","Public warrants (NTRBW) exercised on 47,076 shares for $302,699.","Private investor warrants exercised on 778,041 shares for $5,002,804.","Total shares from exercises: 845,172; disclosure voluntary under Item 7.01."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140126,"accession_number":"0001213900-25-073116","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["3.02","5.03","9.01"],"status":"ready","headline":"Nutriband issues Series A Preferred stock dividend of 3,008,643 shares to common holders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock dividend of Series A Preferred Stock: 1 share for every 4 common shares, issued Aug 5, 2025.","Total of 3,008,643 Series A Preferred shares issued based on July 25, 2025 record date.","Series A Preferred is non-voting; converts to common stock upon FDA approval of AVERSA technology.","Board authorized up to 10,000,000 shares; initially 2,788,678 then increased by correction.","Shares are restricted and held by transfer agent; not transferable until SEC registration and Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140125,"accession_number":"0001213900-25-064355","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Nutriband declares Series A Convertible Preferred stock dividend; record date July 25, 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Board authorized 2,788,678 shares of Series A Convertible Preferred Stock (non-voting).","Dividend of one Series A Preferred share for every four common shares owned.","Record date: July 25, 2025; conversion to common only after FDA approval of AVERSA transdermal products.","Series A Preferred shares eligible for dividends declared on common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157769,"accession_number":"0001213900-25-030175","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband signs Associate Partnership with MLS team Charlotte FC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Charlotte FC (Major League Soccer) to build brand visibility.","Focus on AI Tape, manufactured locally at Pocono facility in North Carolina.","Also intends to promote AVERSA abuse-deterrent patch technology.","No financial terms disclosed; partnership is marketing-focused."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176142,"accession_number":"0001213900-25-013266","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband formalizes exclusive Aversa Fentanyl partnership with Kindeva; potential $80-200M US sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Signed addendum formalizing exclusive development partnership for Aversa Fentanyl with Kindeva Drug Delivery.","Partnership based on shared development costs in exchange for milestone payments.","Aversa Fentanyl combines Nutriband's abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch.","Estimated peak annual US sales potential of $80M to $200M.","AVERSA technology protected by patents in 46 countries including US, Europe, Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176141,"accession_number":"0001213900-25-012896","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband receives USPTO Notice of Allowance for Aversa abuse deterrent patent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notice of Allowance received Feb 3, 2025 for patent app 18/369,241 covering Aversa abuse deterrent transdermal systems.","US patent expected to issue after administrative processes; expands US IP protection for abuse deterrent transdermal portfolio.","Lead product Aversa Fentanyl could become first abuse-deterrent opioid patch; potential peak US sales $80-200M per Health Advances.","Aversa technology already protected by patents in 46 countries including US, Europe, Japan, China, Canada, Mexico, Australia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176140,"accession_number":"0001213900-25-007938","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nutriband stockholders elect directors, approve auditor and stock plan at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with ~99% of votes cast; each received over 7.4M for votes.","Ratification of Sadler, Gibb & Associates as auditor approved: 7,383,020 for, 65,113 against.","2024 Amended and Restated Stock Option Plan approved: 7,262,469 for, 185,664 against.","Say-on-pay advisory vote passed: 7,420,065 for, 28,068 against; frequency set to 1 year.","Approximately 67.1% of outstanding shares voted (7,448,133 of 11,106,185)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193049,"accession_number":"0001213900-24-113463","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband extends AVERSA patent to Macao; now covered in 46 countries","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Macao IP Office assigned patent number J/9010 with entry date December 17, 2024.","AVERSA abuse-deterrent technology now patented in 46 countries and territories.","Company targets FDA submission for AVERSA Fentanyl in first half of 2025.","AVERSA Fentanyl has potential peak US sales of $80M to $200M per Health Advances report.","Partnership with Kindeva Drug Delivery for lead product using FDA-approved fentanyl patch system."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193048,"accession_number":"0001213900-24-092676","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband receives Chinese patent for AVERSA abuse-deterrent transdermal system","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CNIPA fully issued Patent No. ZL 202211158031 for 'Abuse and Misuse Deterrent Transdermal System' related to AVERSA technology.","Patent covers taste aversion to prevent abuse of opioid patches; previously allowed in September 2024.","AVERSA IP portfolio now includes granted patents in US, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China.","Lead product under development is an abuse-deterrent fentanyl patch incorporating AVERSA technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209416,"accession_number":"0001213900-24-079788","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband announces $1 million share repurchase program; reaffirms AVERSA Fentanyl NDA timeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share buyback program authorizes repurchase of up to $1,000,000 of common stock.","Company had 11,106,185 shares outstanding as of September 16, 2024.","Maintains target to submit AVERSA Fentanyl NDA to FDA in Q1/Q2 2025.","Repurchase program effective immediately; no expiration date disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227431,"accession_number":"0001213900-24-049007","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K/A","filed_at":"2024-06-03T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Nutriband amends 8-K to disclose warrants omitted from prior conversion filing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment adds 152,460 warrants to purchase common stock at $6.43 per share, expiring May 14, 2029.","Warrants were issued to TII Jet Services LDA alongside 76,230 shares at $4.00 conversion of $300K debt.","Original 8-K filed May 21, 2024 omitted the warrant description; corrected via Amendment No. 1.","Conversion and warrant issuance are unregistered sales of equity securities pursuant to Item 3.02.","Exhibit 10.34 contains the May 22, 2024 Amendment to Note Conversion Agreement detailing the modification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227434,"accession_number":"0001213900-24-045330","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Nutriband converts $300K debt into 76,230 shares at $4.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Converted $300,000 principal plus $4,921.79 accrued interest on a Creditline Promissory Note.","Conversion price of $4.00 per share; 76,230 shares of common stock issued to TII Jet Services LDA.","Effective May 14, 2024; shares issued as unregistered securities under an exemption.","Reduces outstanding note debt while increasing share count and diluting existing holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227433,"accession_number":"0001213900-24-044425","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nutriband appoints Sergei Glinka as director effective May 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Sergei Glinka as a director effective May 15, 2024.","Glinka, 58, has been Commercial Manager at TG Biochemicals Limited (Cyprus) since 2019.","He has also served on the board of GST Investments OÜ (Estonia) since 2019.","He graduated from Tallinn Merchant Marine School in 1986."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227432,"accession_number":"0001213900-24-035276","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nutriband raises $8.4M in Regulation S equity offering of units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 2.1M units at $4.00 each, each unit comprising one common share and warrant to buy two shares.","Warrants exercisable at $6.43 per share, cash only, expiring April 19, 2029.","Total gross proceeds of $8.4M from European investors under Regulation S exemption.","Warrants exercisable immediately; no registration statement for shares or warrants.","Proceeds to be used for general corporate purposes (not specified)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246302,"accession_number":"0001213900-24-027338","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Nutriband grants stock options to CEO, President, CFO, COO, CSO and amends stock plan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Item 3.02: Unregistered sales of options to purchase 97,500 shares each to CEO Gareth Sheridan and President Serguei Melnik at $2.61/share.","Options also granted to CFO Gerald Goodman (75,000 shares), COO Alan Smith (70,000), CSO Jeff Patrick (25,000), and others at $2.37/share.","Item 8.01: Board adopted amendment to 2021 Employee Stock Option Plan, increasing shares from 875,000 to 1,400,000.","Amendment to be submitted to stockholders at 2025 Annual Meeting; if not approved within one year, void and options issued pending approval null.","Item 3.02 also includes a warrant to purchase 15,000 shares to counsel Michael Paige at $2.37/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246301,"accession_number":"0001213900-24-006496","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nutriband stockholders elect six directors, ratify auditor, approve say on pay, choose 1-year frequency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected: Sheridan, Melnik, Hamilton, Bujoreanu, Mancas, Gram each with >5.2M votes for.","Ratification of Sadler, Gibb & Associates as auditor: 5,720,198 for, 27,097 withheld, 56 against.","Advisory say on pay approved: 5,299,717 for, 46,012 withheld, 637 against, 400,985 abstain.","Frequency of say on pay set at 1 year: 5,319,922 votes for 1 year, 18K for 3 years, 1,334 for 2 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246300,"accession_number":"0001213900-24-003023","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband signs commercial development & clinical supply agreement with Kindeva for Aversa Fentanyl patch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kindeva to perform commercial process development & supply clinical materials for FDA abuse liability study.","Agreement replaces prior feasibility deal; moves AVERSA Fentanyl toward NDA filing.","AVERSA Fentanyl estimated peak annual US sales $80M-$200M per Health Advances 2022 market analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263739,"accession_number":"0001213900-23-100093","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2023-12-29T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Nutriband converts $2M note into 1.03M shares at $2.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holder TII Jet Services LDA converted $2M principal plus $53,440 accrued interest into 1,026,720 common shares at $2.00/share.","Conversion reduces outstanding debt by $2M and increases common shares outstanding by about 1.03 million.","Shares issued under an exemption from registration; no underwriter involved.","The converted note was originally dated July 13, 2023, with a maturity of July 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280949,"accession_number":"0001213900-23-056939","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2023-07-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nutriband replaces $2M credit line with $5M facility at 7% for AVERSA Fentanyl","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Secured $5M credit line at 7% interest, maturing July 13, 2026, replacing prior $2M facility.","Funds for AVERSA™ Fentanyl FDA approval and commercial manufacturing via Kindeva Drug Delivery.","No conversion rights; advances contingent on starting Kindeva work related to NDA filing.","Interest payable annually each Dec 31 starting 2023; prepayment allowed without penalty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299613,"accession_number":"0001213900-23-050464","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K/A","filed_at":"2023-06-21T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Nutriband terminates dual listing on MERJ Upstream effective May 31, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Only one shareholder listed 250,000 shares on Upstream; those shares transferred back to transfer agent.","Termination has no effect on the continued Nasdaq Capital Market listing of NTRB common stock.","Agreement with MERJ DEP Ltd dated Jan 5, 2023 terminated effective May 31, 2023.","Global shareholders (non-U.S./Canadian) lose access to this alternative listing venue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319746,"accession_number":"0001213900-23-023937","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband secures $2M credit line for AVERSA Fentanyl commercialization","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Three-year $2,000,000 credit line at 7% interest, non-convertible to common stock.","Proceeds to fund FDA approval process and commercial manufacturing of AVERSA Fentanyl.","AVERSA Fentanyl is an abuse-deterrent fentanyl transdermal system using proprietary technology.","Potential peak annual US sales estimated at $80M-$200M per 2022 market analysis.","Financing is non-dilutive, supporting growth strategy without equity dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319745,"accession_number":"0001213900-23-001034","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband dual-lists on Upstream trading platform under ticker NTRB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Common stock (NTRB) begins trading on Upstream on Jan 5, 2023 at 10:00am EST.","U.S. and Canadian investors may only trade existing shares for liquidation.","Nutriband offers a commemorative digital collectible NFT with claim code NTRB!.","Dual listing aims to expand shareholder base and provide global access via blockchain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337957,"accession_number":"0001213900-22-084014","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2022-12-30T23:59:59+00:00","items":["3.02","5.02","5.07"],"status":"ready","headline":"Nutriband grants stock options to directors/officers; annual meeting re-elects all six directors and ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Dec 9, 2022, board approved stock options totaling 107,500 shares to seven directors and officers at exercise prices of $3.53 or $3.88.","CEO Gareth Sheridan and director Serguei Melnik each received 25,000 options at $3.88; other recipients got 20,000, 10,000, or 7,500 options at $3.53.","At Dec 9 annual meeting, all six director nominees were elected with >5M votes For; auditors Sadler, Gibb & Associates ratified with 6,165,208 For votes.","Broker non-votes of 527,151 were present for director election; no non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337956,"accession_number":"0001213900-22-062369","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband files to dual-list common stock on Upstream digital securities platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Application submitted to dual list NTRB shares on Upstream, a trading app for digital securities and NFTs.","Upstream is powered by Horizon Fintex and MERJ Exchange Limited; approval subject to MERJ acceptance.","Dual listing aims to access a global investor base trading with USDC, credit/debit, PayPal, and USD.","As an existing Nasdaq issuer, Nutriband's listing standards are expected to comply with MERJ Listing Rules.","CEO Gareth Sheridan states dual listing will help reach untapped international markets and enhance liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355318,"accession_number":"0001213900-22-049711","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2022-08-19T23:59:59+00:00","items":["3.02","5.02"],"status":"ready","headline":"Nutriband grants stock options to CEO, Chairman, CFO, and other officers totaling ~137K shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Gareth Sheridan receives 29,167 options at $4.50; Chairman Serguei Melnik 29,167 at $4.50; CFO Gerald Goodman 23,333 at $4.09.","COO Alan Smith 11,667 options at $4.09; CSO Jeff Patrick 23,337; CTO Patrick Ryan 11,667; Director Dianna Mather 8,750, all at $4.09.","Options are for services in fiscal 2023; exercise prices equal fair value on August 1, 2022, adjusted for 7-for-6 forward split effective August 12, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355317,"accession_number":"0001213900-22-046093","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Nutriband announces 7:6 forward stock split; effective August 12, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["7:6 forward stock split; each shareholder gets one additional share for every six held as of August 15 record date.","Shares outstanding increase from 6,684,673 to ~7,798,785; authorized shares rise from 250M to 291,666,666.","Split-adjusted trading begins August 12 (ex-dividend date); payment date August 25; no fractional shares, rounded up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355316,"accession_number":"0001213900-22-043166","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband receives Canadian patent allowance for AVERSA abuse deterrent transdermal technology","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Canadian Intellectual Property Office issued Notice of Allowance for patent CA 2937649 covering AVERSA transdermal abuse deterrent technology.","Patent adds to existing US and Mexico patents, providing IP protection across North America.","Lead product AVERSA Fentanyl estimated to have peak annual US sales potential of $80M-$200M.","AVERSA technology aims to deter abuse, diversion, and accidental exposure of opioids like fentanyl in transdermal patches."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355315,"accession_number":"0001213900-22-041867","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband announces 7:6 forward stock split effective August 15, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board declares 7:6 forward split of common stock, effective at 12:01AM on August 15, 2022.","Every six pre-split shares convert into seven post-split shares; par value unchanged.","CEO Gareth Sheridan cites goal to create shareholder value following recent milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355314,"accession_number":"0001213900-22-041488","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2022-07-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband cancels 1.2M shares (~15% of outstanding) after final court judgment rescinding 2017 acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Final Judgment permits cancellation of 1,200,000 shares issued in 2017 for rescinded Advanced Health Brands deal.","Cancellation reduces total outstanding shares from ~7.8M to 6.6M, a 15% reduction.","Documentation submitted to American Stock Transfer on July 25; cancellation effective within one business day.","Shares held by defendants in Orlando court case; company recovers stock from rescinded acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355313,"accession_number":"0001213900-22-039511","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2022-07-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband wins court verdict to rescind 2017 acquisition and recover 1.2M shares (~15% of outstanding)","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Circuit Court in Orange County, Florida ruled in favor of Nutriband on all issues, rescinding the Advanced Health Brands acquisition.","Company to recover 1.2 million shares (post-reverse split) representing ~15% of total outstanding shares.","Shares were originally issued as consideration for the 2017 acquisition; recovery reduces share count.","Press release dated July 15, 2022 announced the verdict."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392166,"accession_number":"0001213900-22-004373","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2022-01-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband receives US patent for AVERSA abuse deterrent transdermal technology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO issued patent for 'Abuse and Misuse Deterrent Transdermal System' covering AVERSA platform.","Lead product AVERSA Fentanyl could be first abuse deterrent fentanyl transdermal system.","Expanded pipeline includes AVERSA buprenorphine and AVERSA methylphenidate.","Patents also granted in Europe, Japan, Korea, Russia, Mexico, Australia.","CEO Gareth Sheridan calls it an important milestone for Nutriband."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392165,"accession_number":"0001213900-22-004031","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2022-01-27T23:59:59+00:00","items":["5.02","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Nutriband expands AVERSA abuse-deterrent pipeline to include buprenorphine and methylphenidate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Adds AVERSA buprenorphine and AVERSA methylphenidate (ADHD) to pipeline; lead product AVERSA Fentanyl has $80-200M potential US sales.","CEO Gareth Sheridan and President Serguei Melnik sign 3-year employment agreements at $250k base salary; CFO Gerald Goodman at $210k.","Board grants stock options: Sheridan and Melnik each receive 20,000 shares at $5.34; 13 others get options at $4.85 or $5.34.","Irina Gram-Contulescu elected as new director; annual meeting also ratified auditor Sadler Gibb and approved 2021 Stock Option Plan.","By-laws amended to create CEO role and extend annual meeting window from 6 to 12 months after fiscal year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392164,"accession_number":"0001213900-22-001256","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband signs feasibility agreement with Kindeva to develop abuse deterrent fentanyl patch AVERSA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement combines Nutriband's AVERSA abuse deterrent technology with Kindeva's FDA-approved fentanyl patch.","Partnership focuses on adapting Kindeva's commercial transdermal manufacturing process for AVERSA incorporation.","Kindeva is a CDMO with 50+ years transdermal experience, formerly 3M Drug Delivery Systems.","AVERSA technology covered by patents: US notice of allowance, patents in Europe, Japan, Korea, Russia, Mexico, Australia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392163,"accession_number":"0001213900-22-000118","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2022-01-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband receives Korean patent for abuse-deterrent transdermal system AVERSA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Korean Intellectual Property Office issued full patent titled 'Abuse and Misuse Deterrent Transdermal System'.","Patent supports 4p Therapeutics' AVERSA fentanyl transdermal system using taste aversion.","Company previously received notice of allowance in December 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410492,"accession_number":"0001213900-21-068055","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2021-12-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nutriband announces $1M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share repurchase program authorized to buy back up to $1,000,000 of common stock.","Program announced on December 29, 2021; company had 7,773,962 shares outstanding.","Repurchases may be made through open market or negotiated transactions depending on market conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410491,"accession_number":"0001213900-21-052451","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2021-10-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nutriband signs exclusive manufacturing deal for COVID-19 antibody monitoring patch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive manufacturing agreement via subsidiary Active Intelligence, LLC with Diomics for Diocheck™ patch.","Patch monitors SARS-CoV-2 antibodies post-vaccination and can signal when booster needed.","Allows Nutriband's Pocono Pharma subsidiary to showcase manufacturing capabilities for innovative patch tech.","Agreement effective October 4, 2021; filed as 8-K on October 12, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410490,"accession_number":"0001213900-21-052092","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2021-10-08T23:59:59+00:00","items":["3.02","8.01","5.02"],"status":"ready","headline":"Nutriband completes IPO on Nasdaq, nets $5.8M; elects Serguei Melnik as President","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 1,056,000 units at $6.25/unit, each unit = 1 share + 1 warrant; underwriters' option exercised for 158,400 warrants.","Net proceeds of $5,836,230; common stock and warrants listed on Nasdaq Capital Market effective Oct 1, 2021.","Warrants exercisable at $7.50 per share, expire 5 years from issuance; Representative's warrant for 105,600 shares at 120% of IPO price.","Board elected co-founder Serguei Melnik, previously Secretary, to the office of President on October 8, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410489,"accession_number":"0001213900-21-051123","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2021-10-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nutriband receives USPTO Notice of Allowance for abuse-deterrent transdermal patent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO allowed patent application 16/707,547 on Sept 27, 2021.","Patent covers \"Abuse and Misuse Deterrent Transdermal Systems\".","Company expects U.S. patent to issue after administrative completion.","Strengthens Nutriband's IP portfolio for transdermal delivery platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429295,"accession_number":"0001213900-21-046170","cik":1676047,"company_name":"NutriBand Inc.","ticker":"NTRB","form_type":"8-K","filed_at":"2021-09-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nutriband extends $1.5M note maturity to Sept 30, 2021; delays listing deadline","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended $1.5M promissory note due date from Aug 31, 2021 to Sept 30, 2021.","Extended deadline for completing listing (Section 5.3(a)) to Sept 30, 2021.","Amendment entered Aug 31, 2021 with Pocono Coated Products and Active Intelligence.","Original purchase (Aug 2020): $6M in stock plus $1.5M note for transdermal business assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":41391120.40028695,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}